Assembly Concurrent Resolution ACR 93 declares October 23, 2025, as Aromatic L‑Amino Acid Decarboxylase (AADC) Deficiency Awareness Day and lays out legislative findings about the condition and rare‑disease prevalence. The text describes AADC deficiency as a life‑limiting genetic neurologic disorder that prevents patients from producing dopamine and lists characteristic clinical features, caregiver burdens, and an approximate global case count.
The measure is purely declaratory: it raises visibility and urges public and medical awareness but does not create new programs, funding, or regulatory duties. Its practical value is in signaling state‑level attention that advocates and clinicians may use to press for screening, research, care coordination, or resource development outside the text of the resolution itself.
At a Glance
What It Does
Adopts a nonbinding concurrent resolution recognizing AADC deficiency and reciting factual findings about the disorder and rare‑disease statistics. The resolution urges greater awareness but does not authorize spending, regulatory changes, or new services.
Who It Affects
Patients with AADC deficiency and their caregivers, pediatricians and neurologists who diagnose neurodevelopmental disorders, rare‑disease advocacy organizations, and clinical researchers focused on ultra‑rare genetic disorders. State legislative staff and communications offices will handle any outreach requests generated by the designation.
Why It Matters
For clinicians and advocates, formal recognition can accelerate referrals, improve case finding, and lend weight to fundraising or grant applications. For policymakers and health system planners, it flags a condition with severe functional impact despite extremely small case counts.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
ACR 93 is a one‑page legislative resolution that compiles basic facts about rare diseases and AADC deficiency and then expresses the Legislature’s intent to raise awareness. The bill’s preamble repeats standard rare‑disease metrics (a disease affecting fewer than 200,000 people in the U.S.), cites more than 6,800 rare conditions nationally, and uses national prevalence estimates to frame the urgency of attention to ultra‑rare disorders.
The resolution’s factual recitation describes AADC deficiency biologically — a genetic enzyme deficiency that prevents dopamine synthesis — and clinically, noting failure to reach motor milestones, profound developmental and communication impairments, low muscle tone, involuntary eye movements, and that diagnoses rely on genetic and biochemical testing. The text also includes an estimate of roughly 350 reported cases worldwide, which underscores both the condition’s rarity and the practical difficulty of mounting population‑level responses.Legally, the instrument is a concurrent resolution: it records the Legislature’s view but does not change law or appropriations.
The Legislative Counsel digest and the bill text indicate no fiscal committee action, reflecting the absence of mandated spending. The practical mechanisms by which recognition could matter — increased clinician awareness, more referrals for genetic testing, and leverage for advocacy or research funding — would require separate policy, budgetary, or programmatic steps beyond this resolution.Finally, the bill contains a short administrative clause directing transmittal of the resolution text to the author, which is routine.
If the awareness effort produces increased demand for diagnostic services or specialist care, that demand will play out against existing capacity in pediatric neurology and genetics clinics rather than through any new state program tied to this measure.
The Five Things You Need to Know
ACR 93 is a concurrent resolution adopted by the Legislature — a nonbinding, ceremonial instrument that expresses legislative sentiment but does not create legal obligations or funding.
The resolution’s preamble cites the federal rare‑disease threshold (<200,000 people), states there are more than 6,800 rare diseases, and estimates 25–30 million Americans are affected by rare conditions.
The text describes the biological mechanism: AADC deficiency prevents production of dopamine, which the bill ties to failure to reach basic motor and communication milestones.
The bill reports approximately 350 cases of AADC deficiency documented worldwide, a figure that frames it as an ultra‑rare condition.
The resolution includes a routine administrative instruction directing the Chief Clerk to transmit copies to the author; the Legislative Counsel’s digest flags no fiscal committee action.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings about rare diseases and AADC deficiency
The bill compiles factual statements: a working federal definition of a rare disease (<200,000 affected), an estimate of >6,800 rare diseases, national prevalence estimates, and a concise clinical portrait of AADC deficiency (dopamine synthesis defect, developmental and motor impairments, diagnostic tests). Those findings serve to justify the Legislature’s decision to single out the condition for recognition; they do not establish diagnostic criteria or clinical guidance but can be cited by advocates and clinicians seeking to explain the condition in policy or funding contexts.
Ceremonial recognition
The operative clause records the Legislature’s recognition of an awareness day and uses invitational language rather than mandatory verbs. Because the instrument is a concurrent resolution, the clause has no regulatory effect, creates no entitlement, and does not appropriate funds. Its immediate practical effect is rhetorical: it places the condition on record as a matter of public concern and can be used to justify outreach, awareness campaigns, or commemorative events led by third parties.
Invitation to public and medical communities
The resolution 'encourages' Californians to learn about AADC deficiency and raises awareness among the public and medical providers. The language is hortatory: it signals a preferred action but imposes no reporting, program development, or training obligations on state agencies or health systems. In practice this clause may prompt requests to state communications offices or health departments for informational materials, which are not funded by the bill itself.
Transmittal and fiscal notation
The resolution directs the Chief Clerk to transmit copies to the author for distribution — a procedural step to ensure stakeholders receive the text. The Legislative Counsel’s digest records 'Fiscal Committee: NO,' indicating lawmakers did not identify direct fiscal effects; that simplifies administrative handling but does not preclude downstream costs if awareness leads to increased service utilization.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with AADC deficiency and their families: Greater public recognition can reduce diagnostic delay, improve referral pathways when clinicians are alerted to the condition’s hallmark signs, and strengthen advocacy efforts for research or care funding.
- Pediatricians and neurologists: Heightened awareness may shorten time to diagnosis by prompting earlier genetic or biochemical testing in infants with low muscle tone and developmental delay.
- Rare‑disease advocacy organizations: A formal state recognition provides a credential that can be used to amplify fundraising, educate clinicians, and recruit participants for registries or studies.
- Clinical researchers and biotech sponsors: Publicity around an ultra‑rare disorder can increase visibility for clinical trial recruitment and bolster grant proposals, especially where patient numbers are the limiting factor.
Who Bears the Cost
- State legislative and executive communications staff: Responding to requests for information or coordinating recognition events will consume staff time without statutory reimbursement.
- Health care providers and specialty clinics: Increased awareness can generate more referrals and diagnostic testing demand, potentially straining already limited pediatric neurology and genetic services.
- Small advocacy groups and families: Expectations created by public recognition often translate into more outreach and support responsibilities for nonprofits that lack additional funding.
- Local public health departments (potentially): If constituencies request educational materials or local outreach, departments may need to absorb modest outreach or coordination costs.
Key Issues
The Core Tension
The central tension is between the low‑cost, widely accessible tool of symbolic recognition — which can improve visibility for a tiny, severely affected population — and the absence of any binding commitments to diagnose, treat, or finance care; the resolution raises expectations without allocating the resources that would actually change outcomes for patients.
The resolution trades little immediate cost for visibility, but that trade raises practical questions. Symbolic recognition can mobilize clinicians and funders, yet it can also create expectations for concrete follow‑up — screening programs, care coordination, or research funding — none of which are supplied by the text.
If stakeholders interpret the designation as a commitment, they may press state agencies or the Legislature for resources that the resolution did not authorize or budget.
The bill’s factual claims present another implementation wrinkle. Citing an estimated 'approximately 350 cases worldwide' underscores rarity but may undercount undiagnosed cases and relies on data that can become outdated quickly as diagnostic uptake changes.
Finally, a single‑day designation is useful for publicity but may do little to change clinical practice without parallel investments in provider education, newborn or early‑childhood screening pathways, and reimbursement for genetic testing. Those structural steps require separate policy instruments and funding decisions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.